FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287405742> ?p ?o ?g. }

• W4287405742 endingPage "3293" @default.
• W4287405742 startingPage "3285" @default.
• W4287405742 abstract "Despite advances in treatment, most patients with multiple myeloma (MM) will relapse, and long-term survival remains poor. B-cell maturation antigen (BCMA) is an ideal therapeutic target as it is expressed throughout the disease course with normal tissue expression limited to plasma and some B-cell lineages. This phase 1, multicenter, first-in-human study evaluated the safety and efficacy of KITE-585, an autologous anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory MM (RRMM). Key eligibility criteria included measurable MM and progression, defined by the International Myeloma Working Group Consensus Criteria within 60 days of the last treatment. Patients underwent leukapheresis and subsequently received a 3-day conditioning therapy regimen (cyclophosphamide [300 mg/m2/day] and fludarabine [30 mg/m2/day]). Patients then received a flat dose of 3 × 107 to 1 × 109 KITE-585 CAR T cells in a 3+3 dose-escalation design. The primary endpoint was incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs). Key secondary and exploratory endpoints included efficacy outcomes, incidence of AEs, levels of KITE-585 in blood, serum cytokines, and incidence of anti-BCMA CAR antibodies. Seventeen patients were enrolled, and 14 received KITE-585 with a median follow-up of 12.0 months. The median age of patients was 56 years, 41.2% had an Eastern Cooperative Oncology Group performance status of 1, 92.9% had baseline BCMA expression on plasma cells, and median number of prior therapies was 5.5. No patients experienced a DLT, all patients experienced ≥ 1 grade ≥ 3 treatment-emergent AE (TEAE), and no grade 5 TEAEs were observed. There were no grade ≥ 3 events of cytokine release syndrome, neurologic events, or infections; all were grade 1 or 2, and each occurred in 21.4% of patients. Among all patients infused with KITE-585, 1 patient who received 3 × 107 anti-BCMA CAR T cells experienced a partial response. Median peak CAR T-cell expansion was low (0.98 cells/μL), as were median peak serum levels of CAR-associated cytokines, including interferon-γ (61.45 pg/mL) and interleukin-2 (0.9 pg/mL). KITE-585 demonstrated a manageable safety profile; however, the limited CAR T-cell expansion and associated lack of anti-tumor response in patients with RRMM treated with KITE-585 is consistent with the minimal CAR T-cell activity observed." @default.
• W4287405742 created "2022-07-25" @default.
• W4287405742 creator A5021394406 @default.
• W4287405742 creator A5022520524 @default.
• W4287405742 creator A5023332598 @default.
• W4287405742 creator A5026574827 @default.
• W4287405742 creator A5038235561 @default.
• W4287405742 creator A5039360390 @default.
• W4287405742 creator A5041057399 @default.
• W4287405742 creator A5041161932 @default.
• W4287405742 creator A5050097218 @default.
• W4287405742 creator A5052048627 @default.
• W4287405742 creator A5070096873 @default.
• W4287405742 creator A5070180314 @default.
• W4287405742 creator A5089893290 @default.
• W4287405742 date "2021-01-01" @default.
• W4287405742 modified "2023-09-28" @default.
• W4287405742 title "A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma." @default.
• W4287405742 cites W2003734726 @default.
• W4287405742 cites W2013296669 @default.
• W4287405742 cites W2022900996 @default.
• W4287405742 cites W2038477042 @default.
• W4287405742 cites W2070135451 @default.
• W4287405742 cites W2106887611 @default.
• W4287405742 cites W2153147430 @default.
• W4287405742 cites W2184270030 @default.
• W4287405742 cites W2422962677 @default.
• W4287405742 cites W2471662063 @default.
• W4287405742 cites W2773804840 @default.
• W4287405742 cites W2781388087 @default.
• W4287405742 cites W2787301955 @default.
• W4287405742 cites W2790173378 @default.
• W4287405742 cites W2792061543 @default.
• W4287405742 cites W2795019304 @default.
• W4287405742 cites W2906581363 @default.
• W4287405742 cites W2924578117 @default.
• W4287405742 cites W4252175385 @default.
• W4287405742 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34249462" @default.
• W4287405742 hasPublicationYear "2021" @default.
• W4287405742 type Work @default.
• W4287405742 citedByCount "3" @default.
• W4287405742 countsByYear W42874057422022 @default.
• W4287405742 countsByYear W42874057422023 @default.
• W4287405742 crossrefType "journal-article" @default.
• W4287405742 hasAuthorship W4287405742A5021394406 @default.
• W4287405742 hasAuthorship W4287405742A5022520524 @default.
• W4287405742 hasAuthorship W4287405742A5023332598 @default.
• W4287405742 hasAuthorship W4287405742A5026574827 @default.
• W4287405742 hasAuthorship W4287405742A5038235561 @default.
• W4287405742 hasAuthorship W4287405742A5039360390 @default.
• W4287405742 hasAuthorship W4287405742A5041057399 @default.
• W4287405742 hasAuthorship W4287405742A5041161932 @default.
• W4287405742 hasAuthorship W4287405742A5050097218 @default.
• W4287405742 hasAuthorship W4287405742A5052048627 @default.
• W4287405742 hasAuthorship W4287405742A5070096873 @default.
• W4287405742 hasAuthorship W4287405742A5070180314 @default.
• W4287405742 hasAuthorship W4287405742A5089893290 @default.
• W4287405742 hasConcept C126322002 @default.
• W4287405742 hasConcept C141071460 @default.
• W4287405742 hasConcept C143998085 @default.
• W4287405742 hasConcept C197934379 @default.
• W4287405742 hasConcept C203092338 @default.
• W4287405742 hasConcept C2776364478 @default.
• W4287405742 hasConcept C2776694085 @default.
• W4287405742 hasConcept C2776755627 @default.
• W4287405742 hasConcept C2779263901 @default.
• W4287405742 hasConcept C2781413609 @default.
• W4287405742 hasConcept C31760486 @default.
• W4287405742 hasConcept C535046627 @default.
• W4287405742 hasConcept C71924100 @default.
• W4287405742 hasConcept C90924648 @default.
• W4287405742 hasConceptScore W4287405742C126322002 @default.
• W4287405742 hasConceptScore W4287405742C141071460 @default.
• W4287405742 hasConceptScore W4287405742C143998085 @default.
• W4287405742 hasConceptScore W4287405742C197934379 @default.
• W4287405742 hasConceptScore W4287405742C203092338 @default.
• W4287405742 hasConceptScore W4287405742C2776364478 @default.
• W4287405742 hasConceptScore W4287405742C2776694085 @default.
• W4287405742 hasConceptScore W4287405742C2776755627 @default.
• W4287405742 hasConceptScore W4287405742C2779263901 @default.
• W4287405742 hasConceptScore W4287405742C2781413609 @default.
• W4287405742 hasConceptScore W4287405742C31760486 @default.
• W4287405742 hasConceptScore W4287405742C535046627 @default.
• W4287405742 hasConceptScore W4287405742C71924100 @default.
• W4287405742 hasConceptScore W4287405742C90924648 @default.
• W4287405742 hasIssue "6" @default.
• W4287405742 hasLocation W42874057421 @default.
• W4287405742 hasOpenAccess W4287405742 @default.
• W4287405742 hasPrimaryLocation W42874057421 @default.
• W4287405742 hasRelatedWork W10198250 @default.
• W4287405742 hasRelatedWork W1051628 @default.
• W4287405742 hasRelatedWork W12229326 @default.
• W4287405742 hasRelatedWork W14747713 @default.
• W4287405742 hasRelatedWork W19219843 @default.
• W4287405742 hasRelatedWork W21619 @default.
• W4287405742 hasRelatedWork W3657330 @default.
• W4287405742 hasRelatedWork W4429043 @default.
• W4287405742 hasRelatedWork W5731518 @default.

• next